C3A [HepG2/C3A, derivative of Hep G2 (ATCC HB-8065)] (ATCC® CRL-10741)

Organism: Homo sapiens, human  /  Tissue: liver  /  Disease: hepatocellular carcinoma

Organism Homo sapiens, human
Tissue liver
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease hepatocellular carcinoma
Age 15 years adolescent
Gender male
Ethnicity Caucasian
Applications
This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Derivation
C3A is clonal derivative of Hep G2 that was selected for strong contact inhibition of growth, high albumin production, high production of alpha fetoprotein (AFP) and ability to grow in glucose deficient medium.
Clinical Data
15 years adolescent
Caucasian
male
Genes Expressed
alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen;,complement (C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein)
Cellular Products
alpha-fetoprotein (alpha fetoprotein); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; alpha1 antichymotrypsin; (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen;
complement (C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein); alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein)
Tumorigenic No
Effects
No, in immunosuppressed mice
Yes, in semisolid medium
Comments

As the cells become confluent, there is a marked reduction in AFP secretion and an increase in albumin secretion.

Gluconeogenesis activity is strongly oxgen dependent.

The cells have nitrogen metabolizing activity comparable to perfused rat livers.

There is no evidence of a Hepatitis B virus genome in this cell line.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

    Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
    Medium Renewal: Twice per week
    Cryopreservation
    Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
    Storage temperature: liquid nitrogen vapor phase
    Culture Conditions
    Temperature: 37°C
    STR Profile
    Amelogenin: X,Y
    CSF1PO: 10,11
    D13S317: 9,13
    D16S539: 12,13
    D5S818: 11,13
    D7S820: 10
    THO1: 9
    TPOX: 8,9
    vWA: 17
    Name of Depositor Baylor College of Medicine
    References

    Kelly JH. Permanent human hepatocyte cell line and its use in a liver assist device (LAD). US Patent 5,290,684 dated Mar 1 1994

    Basic Documentation
    Other Documentation
    References

    Kelly JH. Permanent human hepatocyte cell line and its use in a liver assist device (LAD). US Patent 5,290,684 dated Mar 1 1994